102 related articles for article (PubMed ID: 27744566)
1. Progranulin as a predictive factor of response to chemotherapy in advanced biliary tract carcinoma.
Kim JH; Do IG; Kim K; Sohn JH; Kim HJ; Jeon WK; Lee SR; Son BH; Shin JH; Nam H; Kwon HJ; Kim MS; Hong HP; Serrero G; Koo DH;
Cancer Chemother Pharmacol; 2016 Nov; 78(5):1085-1092. PubMed ID: 27744566
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer.
Furuse J; Okusaka T; Ohkawa S; Nagase M; Funakoshi A; Boku N; Yamao K; Yamaguchi T; Sato T
Cancer Chemother Pharmacol; 2009 Dec; 65(1):113-20. PubMed ID: 19404641
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer.
Hong YS; Lee J; Lee SC; Hwang IG; Choi SH; Heo JS; Park JO; Park YS; Lim HY; Kang WK
Cancer Chemother Pharmacol; 2007 Aug; 60(3):321-8. PubMed ID: 17143602
[TBL] [Abstract][Full Text] [Related]
4. CA19-9 kinetics during systemic chemotherapy in patients with advanced or recurrent biliary tract cancer.
Takahara N; Nakai Y; Isayama H; Sasaki T; Saito K; Noguchi K; Suzuki T; Nakamura T; Sato T; Ishigaki K; Hakuta R; Takeda T; Uchino R; Mizuno S; Kogure H; Tada M; Koike K
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1105-1112. PubMed ID: 29038848
[TBL] [Abstract][Full Text] [Related]
5. Patients with recurrent biliary tract cancer have a better prognosis than those with unresectable disease: retrospective analysis of a multi-institutional experience with patients of advanced biliary tract cancer who received palliative chemotherapy.
Ikezawa K; Kanai M; Ajiki T; Tsukamoto T; Toyokawa H; Terajima H; Furuyama H; Nagano H; Ikai I; Kuroda N; Awane M; Ochiai T; Takemura S; Miyamoto A; Kume M; Ogawa M; Takeda Y; Taira K; Ioka T
J Hepatobiliary Pancreat Sci; 2014 Feb; 21(2):98-104. PubMed ID: 23798367
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Value of Progranulin in Patients with Colorectal Cancer Treated with Curative Resection.
Koo DH; Do IG; Oh S; Lee YG; Kim K; Sohn JH; Park SK; Yang HJ; Jung YS; Park DI; Jeong KU; Kim HO; Kim H; Serrero G; Chun HK;
Pathol Oncol Res; 2020 Jan; 26(1):397-404. PubMed ID: 30378010
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors in patients with advanced biliary tract cancer receiving chemotherapy.
Saisho T; Okusaka T; Ueno H; Morizane C; Okada S
Hepatogastroenterology; 2005; 52(66):1654-8. PubMed ID: 16334750
[TBL] [Abstract][Full Text] [Related]
8. Different relation between ERCC1 overexpression and treatment outcomes of two platinum agents in advanced biliary tract adenocarcinoma patients.
Hwang IG; Jang JS; Do JH; Kang JH; Lee GW; Oh SY; Kwon HC; Jun HJ; Lim HY; Lee S; Chi KC; Lee SJ
Cancer Chemother Pharmacol; 2011 Oct; 68(4):935-44. PubMed ID: 21298384
[TBL] [Abstract][Full Text] [Related]
9. Optimum chemotherapy for the management of advanced biliary tract cancer.
Ghosn M; Kourie HR; El Rassy E; Chebib R; El Karak F; Hanna C; Nasr D
World J Gastroenterol; 2015 Apr; 21(14):4121-5. PubMed ID: 25892861
[TBL] [Abstract][Full Text] [Related]
10. Regional chemotherapy in biliary tract cancers--a single institution experience.
Melichar B; Cerman J; Dvorák J; Jandík P; Mergancová J; Melicharová K; Tousková M; Krajina A; Voboril Z
Hepatogastroenterology; 2002; 49(46):900-6. PubMed ID: 12143237
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma.
Park SH; Park YH; Lee JN; Bang SM; Cho EK; Shin DB; Lee JH
Cancer; 2006 Jan; 106(2):361-5. PubMed ID: 16342166
[TBL] [Abstract][Full Text] [Related]
12. A Population-Based Retrospective Study of Biliary Tract Cancers in Alberta, Canada.
Beaulieu C; Lui A; Yusuf D; Abdelaziz Z; Randolph B; Batuyong E; Ghosh S; Bathe OF; Tam V; Spratlin JL
Curr Oncol; 2021 Jan; 28(1):417-427. PubMed ID: 33450805
[No Abstract] [Full Text] [Related]
13. Prognostic factors and predictive model in patients with advanced biliary tract adenocarcinoma receiving first-line palliative chemotherapy.
Park I; Lee JL; Ryu MH; Kim TW; Sook Lee S; Hyun Park D; Soo Lee S; Wan Seo D; Koo Lee S; Kim MH
Cancer; 2009 Sep; 115(18):4148-55. PubMed ID: 19536892
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study.
Zhu AX; Meyerhardt JA; Blaszkowsky LS; Kambadakone AR; Muzikansky A; Zheng H; Clark JW; Abrams TA; Chan JA; Enzinger PC; Bhargava P; Kwak EL; Allen JN; Jain SR; Stuart K; Horgan K; Sheehan S; Fuchs CS; Ryan DP; Sahani DV
Lancet Oncol; 2010 Jan; 11(1):48-54. PubMed ID: 19932054
[TBL] [Abstract][Full Text] [Related]
15. Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer.
Lim KH; Han SW; Oh DY; Im SA; Kim TY; Bang YJ
Oncology; 2012; 83(2):57-66. PubMed ID: 22760079
[TBL] [Abstract][Full Text] [Related]
16. Prognostic immunohistochemical biomarkers of chemotherapy efficacy in biliary tract cancer: A systematic review and meta-analysis.
Belkouz A; Labeur TA; Dierks J; Dijk F; van Oijen MGH; Verheij J; van Gulik TM; van de Vijver MJ; Wilmink H; Punt CJA; Klümpen HJ
Crit Rev Oncol Hematol; 2019 Sep; 141():82-94. PubMed ID: 31255992
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy versus Best Supportive Care in Advanced Biliary Tract Carcinoma: A Multi-institutional Propensity Score Matching Analysis.
Ji JH; Kim YS; Park I; Lee SI; Kim RB; Park JO; Oh SY; Hwang IG; Jang JS; Song HN; Kang JH
Cancer Res Treat; 2018 Jul; 50(3):791-800. PubMed ID: 28838033
[TBL] [Abstract][Full Text] [Related]
18. Progranulin and short-term outcome in patients with acute ischaemic stroke.
Xie S; Lu L; Liu L; Bi G; Zheng L
Eur J Neurol; 2016 Mar; 23(3):648-55. PubMed ID: 26728399
[TBL] [Abstract][Full Text] [Related]
19. Body mass index and weight change during initial period of chemotherapy affect survival outcome in advanced biliary tract cancer patients.
Kang J; Lee SH; Son JH; Lee JW; Choi YH; Choi JH; Paik WH; Ryu JK; Kim YT
PLoS One; 2018; 13(4):e0195118. PubMed ID: 29608578
[TBL] [Abstract][Full Text] [Related]
20. Metabolic Characteristics of Advanced Biliary Tract Cancer Using 18F-Fluorodeoxyglucose Positron Emission Tomography and Their Clinical Implications.
Cho KM; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
Oncologist; 2015 Aug; 20(8):926-33. PubMed ID: 26099746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
